Audio Interview

Monkeypox: etiopathogenesis, prevention, and treatments

Published on November 10, 2022   21 min

Other Talks in the Playlist: Research and Clinical Interviews

Please wait while the transcript is being prepared...
Interviewer: Today, I'm interviewing Dr. Dennis Hruby, Chief Scientific Officer, SIGA Technologies, Inc., on monkeypox virus. I should be seeking to learn the nature of the virus, whether it is contagious, infectious, or both. The nature of the disease, what is known as a viral host interaction and viral replication. How the disease could be prevented and treated and most important, what should government's health services and people generally do? SIGA Technologies produces tecovirimat, a therapy for treating monkeypox. A declaration of financial interest accompanies this interview. Dr. Hruby, thank you for sparing the time for this interview. May I ask you to first provide some context. How concerned should we be? By we, I mean governments, health authorities, and individuals. Dr. Hruby. Dr. Hruby: I think we should be very concerned. Pox virologists such as myself have worried about monkeypox for decades. It's been percolating in Africa. Cases have been on the increase and it's quite a serious disease there with up to 10 percent of individuals infected dying. I think we always assumed it would be a threat to the rest of the world. I don't know that we necessarily envisioned it coming into the population in the way that it has. But now that it's here, it's something we want to pay attention to and try to contain because the longer this virus incubates and passages in the human, the more chance there is that it may adapt and either increase its virulence or its ability to spread.

Monkeypox: etiopathogenesis, prevention, and treatments

Embed in course/own notes